Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Kidney (renal cell) cancer
Trial Type:  Treatment
Treatment/Intervention:  antiangiogenesis therapy
Trial Status:  Active
Trial Phase:  Phase III
Results 1-8 of 8 for your search:
Start Over
Clinical Trial to Assess the Importance of Nephrectomy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P070144, NCT00930033
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S0931, U10CA032102, NCI-2011-02028, SWOG-S0931, NCT01120249
Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-30073, EU-21022, PFIZER-EORTC-30073, NCT01099423
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AGS-003-007, 2012-000871-17, NCT01582672
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP311736, NCT01599754
Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 16037 / AN 33/11, 2011-004396-36, NCT01613846
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-214, 2014-001750-42, NCT02231749
A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: WO29637, 2014-004684-20, NCT02420821
Start Over